Gilead Continues Immuno-oncology Spree with US$21 B Immunomedics Buy

By Michelle Liu

Pharma Deals Review: Vol 2020 Issue 9 (Table of Contents)

Published: 18 Sep-2020

DOI: 10.3833/pdr.v2020.i9.2562     ISSN: 1756-7874

Section: Mergers & Acquisitions



In the largest M&A deal of 2020 so far, Gilead Sciences has agreed to pay US$21 B to acquire Immunomedics, a biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details